Roxus® ED Nasal Spray Now Available in the U.S.: Peak Blood Levels in About 10 Minutes, Not an Hour

LTR Pharma launches Roxus ED nasal spray in the U.S. via telemedicine, bypassing FDA approval.

What the company is saying

LTR Pharma Limited (ASX:LTP) is announcing the U.S. availability of Roxus, a prescription nasal spray for erectile dysfunction delivering vardenafil through proprietary intranasal technology. The company emphasizes Roxus’s rapid onset, citing clinical studies where peak blood levels are reached in a median of about 10 minutes, compared to 45–60 minutes for tablets, and highlights that men 65+ achieve this with a quarter of the tablet dose. Messaging focuses on speed, discretion, and patient experience, with Executive Chairman Lee Rodne and Dr. Amy Pearlman, a urologist and advisory board member, providing supportive remarks. The company stresses that Roxus uses the same formulation as SPONTAN, which has been available in Australia for two years. Distribution is handled through a partnership with Shed’s Mavrox telemedicine platform, with prescriptions filled by Strive Pharmacy, and the process is described as streamlined and discreet. LTR Pharma is transparent that Roxus is a compounded medication, not reviewed or approved by the FDA, and provides a list of common side effects and contraindications. The announcement also notes that SPONTAN is advancing through the U.S. FDA 505(b)(2) pathway toward a Phase III study.

What the data suggests

The announcement provides specific clinical pharmacokinetic data: Roxus’s nasal spray formulation achieves peak blood levels in a median of about 10 minutes, compared to 45–60 minutes for oral vardenafil tablets, and does so at a quarter of the tablet dose in men 65 and older. These figures are based on a peer-reviewed Phase 1 study of SPONTAN, the same formulation used in Roxus, but no head-to-head clinical outcome data or patient-reported efficacy is disclosed. The product is available immediately nationwide via telemedicine, with a clear process for prescription and fulfillment. Roxus is not FDA-approved and is classified as a compounded medication, limiting its regulatory standing and potentially its commercial uptake. No financial data, sales projections, or prescription volume targets are provided, so commercial impact cannot be assessed. The only forward-looking element is the mention of SPONTAN’s progress toward a planned Phase III study in the U.S. FDA process.

Analysis

The announcement's tone is upbeat, emphasizing the U.S. launch of Roxus and its clinical advantages over oral ED medications. Most claims are realised and supported by disclosed clinical data (e.g., time to peak blood levels, dose comparison, and availability via telemedicine). However, some language inflates the impact, such as statements about 'changing the experience' and offering 'speed, discretion, and spontaneity,' which are qualitative and not backed by patient outcome data. The only forward-looking claim relates to SPONTAN's FDA pathway, which is clearly separated from the Roxus launch. No financial or sales data are disclosed, so the true signal cannot exceed weak_positive. The benefits of Roxus availability are immediate, and there is no indication of a large capital outlay or deferred returns.

Risk flags

• ●Roxus is not reviewed or approved by the U.S. FDA and is only available as a compounded medication, which limits its marketability, insurance coverage, and prescriber confidence. This regulatory gap increases the risk of limited commercial uptake and potential future legal or compliance challenges.
• ●No financial figures, sales targets, or prescription volume data are disclosed, making it impossible to assess the commercial impact or revenue trajectory from this launch. The lack of quantitative guidance leaves investors without a basis to evaluate near-term financial upside.
• ●The clinical data cited are pharmacokinetic (time to peak blood levels) rather than patient outcome data, and no head-to-head studies with other ED treatments are provided. This creates uncertainty about real-world efficacy, patient satisfaction, and competitive differentiation.
• ●As a compounded medication, Roxus is only available for patients whose prescriber determines that their needs are not met by an available FDA-approved drug, which may restrict the addressable market and expose the company to regulatory scrutiny if prescribing practices are questioned.

Bottom line

LTR Pharma’s U.S. launch of Roxus offers a rapid-onset, intranasal ED treatment through telemedicine, but the product’s compounded, non-FDA-approved status sharply limits its commercial potential and regulatory standing. The company provides credible pharmacokinetic data supporting faster absorption than tablets, but omits any financial, sales, or patient outcome metrics, leaving the commercial impact unquantified. The partnership with Mavrox and Strive Pharmacy enables immediate distribution, but insurance reimbursement and prescriber adoption may be low given regulatory constraints. Investors should recognize that while the product is available now, its market penetration and revenue contribution are highly uncertain without further disclosure. The most important takeaway is that Roxus’s U.S. launch is operationally real but financially opaque, and future updates on sales, regulatory progress, or broader FDA approval will be critical to reassess its value.

Announcement summary

(ASX:LTP) LTR Pharma Limited announced that Roxus®, a prescription nasal spray for erectile dysfunction (ED) delivering vardenafil, is now available to men across the U.S. Roxus uses LTR Pharma's proprietary intranasal spray technology and delivers the same type of ED medicine as Viagra®, but via the nose instead of orally. The intranasal vardenafil formulation in Roxus is the same as that used in SPONTAN®, LTR Pharma's nasal spray prescribed in Australia for the past two years. In clinical studies, including a peer-reviewed Phase 1 study, the spray reached peak blood levels in a median of about 10 minutes, compared to 45 to 60 minutes for vardenafil tablets. Men aged 65 and older reached peak levels just as quickly, and the spray achieved this with a quarter of the tablet dose. Roxus is designed to avoid delays caused by heavy meals, as it is absorbed through the nose rather than the stomach. Lee Rodne, Executive Chairman of LTR Pharma, stated that Roxus changes the experience for men and their partners by being effective within 5-10 minutes. Dr. Amy Pearlman, urologist and member of LTR Pharma's Scientific Advisory Board, commented that Roxus offers speed, discretion, and spontaneity in ED treatment. LTR Pharma has partnered with Shed, whose men's health telemedicine platform Mavrox brings Roxus to men nationwide. To obtain Roxus, men complete an online health assessment at Mavrox.com/Roxus, which is reviewed by a licensed U.S. provider, and if appropriate, Strive Pharmacy fills and ships the prescription. Roxus is also available through in-person healthcare providers. Roxus is a compounded medication prepared for individual patient needs based on a valid prescription and is not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Common side effects include headache, flushing, runny or stuffy nose, indigestion, and temporary nasal discomfort. SPONTAN is progressing through the U.S. FDA 505(b)(2) pathway toward a planned Phase III study.

Disagree with this article?